Headquartered in Staunton, Cadence Inc. celebrates its 40th anniversary
Established in July 1985 by engineer Martin Lightsey, Cadence has grown into a vertically integrated global partner, committed to advancing patient outcomes in collaboration with its OEM customers, the release said. The company offers comprehensive contract manufacturing services from initial design and development through manufacturing and full supply chain management of medical devices worldwide.
'Forty years ago, Cadence began with a simple yet powerful vision to provide custom solutions to OEMs through engineering and innovation,' said Cadence's President and CEO Rob Werge. 'Today, we are a highly differentiated provider to MedTech and Pharma OEMs because of our commitment to supporting our customers' success; however, nothing would be possible without the great team of people at Cadence.'
The company now operates eight facilities across the U.S. and Costa Rica and employs approximately 800 people with its corporate headquarters located in Staunton, Virginia. Cadence delivers a wide range of capabilities from finished device assembly and packaging to nearshore operations, CNC grinding, precision machining, metal stamping, deep draw stamping, metal injection molding (MIM), laser processing and plastic injection molding.
These capabilities support a diverse set of surgical end markets, including robotic-assisted surgery (RAS) and minimally invasive surgery (MIS), while also driving deeper collaboration into drug delivery and diagnostics with key customers. Through this vertically integrated approach, it can simplify and consolidate supply chains, providing efficient, cost-effective solutions that help bring life-changing medical technologies to market faster, the release said.
"As part of our commitment to continuous improvement, Cadence has strengthened our New Product Introduction (NPI) process by building a world-class program management team and enhancing our manufacturability (DFM) expertise," the company said in the release. In addition, the company has made investments in its manufacturing footprint — expanding operations and upgrading equipment — to meet growing demand and support increasing product complexity.
In early 2025, Cadence unveiled a refreshed brand to honor its rich heritage while reflecting its evolution as a trusted leader in MedTech manufacturing, the company said in the release. "As we enter our fifth decade, Cadence remains committed to delivering innovative solutions that improve patient outcomes and support the development of next-generation medical technologies."
'We're proud of the journey that brought us here and even more excited about the future we are building,' said Werge.
More: After 39 years, architectural firm Frazier Associates closes in Staunton
More: Augusta school board candidate charged with misdemeanor assault
Monique Calello is a reporter at The News Leader. Story ideas always welcome. Connect with her at mcalello@newsleader.com. Support local journalism and subscribe to us at newsleader.com.
This article originally appeared on Staunton News Leader: Headquartered in Staunton, Cadence celebrates its 40th anniversary
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
NVIDIA Corporation (NVDA) Could Be In Great Shape In China, Says Jim Cramer
We recently published . NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks Jim Cramer recently discussed. NVIDIA Corporation (NASDAQ:NVDA) has started to become a regular feature on Cramer's morning show as it solidifies its position as the world's most valuable company. In his earlier remarks about the firm, the CNBC TV host has praised the firm's CEO, Jensen Huang, and his success in convincing the Trump administration to lift GPU sales restrictions on China. Once the restrictions were lifted, the market started speculating whether NVIDIA Corporation (NASDAQ:NVDA) could meet Chinese demand. Cramer discussed this issue in the context of EDA provider Cadence's recent results: 'By the way, Cadence, that is, when people look at Cadence, the number one partner is NVIDIA. Now NVIDIA also has the story out there, but not confirmed by me, that there's, the H20 orders from China are huge. There had been some talk that maybe they wouldn't be. Cadence is a fantastic company. And I think that that was the sign that NVIDIA is in great shape in China. NVIDIA's doing so well, what are you going to do? It just keeps, it's just relentless.' Here's what he said earlier about NVIDIA Corporation (NASDAQ:NVDA): 'Okay, I'm getting a lot of pushback for my like of Jensen Huang, saying he's really a globalist. It's not what we want. I'm saying, if everything is based on his chips, we are a new kind of reserve currency. And it's kind of exciting. . .new semiconductor, it's another thing that we're great at. That's Jensen. And Jensen, see a lot of this is what it's written on, what are they going to build on. . .and if you have to write on NVIDIA, David, instead of Huawei, the Chinese could end up being the pitiful, helpless giant.' While we acknowledge the potential of NVDA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Will Healthcare Growth Help STE Beat on Q1 Earnings?
STERIS plc STE is scheduled to release first-quarter fiscal 2026 results on Aug. 7, after market close. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.74, which surpassed the Zacks Consensus Estimate by 5.79%. STE beat on earnings in three of the trailing four quarters and met once, delivering an average surprise of 2.05%. Q1 Estimates for STE The Zacks Consensus Estimate for revenues is pegged at $1.36 billion, suggesting an increase of 6.2% from the year-ago reported figure. The Zacks Consensus Estimate for EPS is pegged at $2.32, indicating a year-over-year increase of 14.3%. Estimate Revision Trend Ahead of STE's Q1 Earnings Estimates for earnings have remained constant at $2.32 per share in the past 30 days. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Healthcare In the previous quarter, growth across consumables and services was robust, favored by procedure volumes in the United States as well as price and market share gains. We expect this trend to have continued in the fiscal first quarter as well. The company, however, maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the first-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to have remained robust despite ongoing shipment issues due to customer project delays. Our model projects the segment's revenues to improve 5.1% from the year-ago reported figure. Applied Sterilization Technologies ('AST') In the fiscal first quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, in the previous quarter, capital equipment shipments more than doubled compared to the prior year, which exceeded the company's expectations. We expect this trend to have continued in the fiscal first quarter. In line with this, global MedTech customers are once again expected to have remained stable and the company is likely to have experienced an increase in bioprocessing demand. We expect these to have contributed to STE's top-line performance in the to-be-reported quarter. Per our model, AST segment's revenues for the quarter are likely to increase 6.3% year over year. STERIS plc Price and EPS Surprise STERIS plc price-eps-surprise | STERIS plc Quote The segment's fiscal fourth-quarter 2025 revenues declined year over year as strong growth in consumables and services was offset by a decline in capital equipment revenue. This trend might have continued in the to-be-reported quarter. However, the segment's margin is expected to have benefited from a favorable mix, pricing, and the divestiture of the CECS business in the to-be-reported quarter. Our model projects the segment's revenues to increase 5.5% year over year. What Our Model Suggests for STE Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here. Earnings ESP: STERIS has an Earnings ESP of -3.24%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #3. Stocks Worth a Look Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Exact Sciences EXAS has an Earnings ESP of +475.00% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2025 results on Aug. 6. You can see the complete list of today's Zacks #1 Rank stocks here. EXAS' earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 48.8%. As per the Zacks Consensus Estimate, the company's second-quarter EPS may increase 77.8% from the year-ago quarter's figure. Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%. Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Dexcom CEO Kevin Sayer to step down
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom CEO Kevin Sayer will step down after leading the diabetes tech company for a decade. Current Chief Operating Officer Jake Leach will become CEO on Jan. 1, 2026, and join the firm's board of directors, according to a Wednesday announcement. Sayer will help with the transition and remain executive chairman of Dexcom's board of directors. Sayer said in a statement that the decision was the result of the board's succession planning and confidence that Leach is the right leader to continue the company's growth. 'There is nobody that I trust more than Jake to lead the company into the future,' Sayer told investors on a Wednesday earnings call. Leach has worked at Dexcom for 21 years, since the company launched its first product. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. Dexcom, which makes continuous glucose monitors, has faced growing competition in the sector, as Abbott expands integrations with automated insulin delivery systems and the Food and Drug Administration authorizes longer-lasting implantable sensors. Dexcom and Abbott last year launched the first over-the-counter glucose sensors. BTIG analyst Marie Thibault said Leach's appointment is not a surprise, as he has been promoted multiple times and has become more visible to investors. J.P. Morgan analyst Robbie Marcus added that the change had been telegraphed for some time. Still, 'there's always some nervousness following the retirement of a long-time CEO,' Marcus wrote. 'Especially one that has transformed a company and product category while creating significant shareholder value like Kevin did.' When asked about his vision for Dexcom as a new CEO, Leach said he is looking to expand global access to the company's devices. 'We're seeing good progress in our growth globally, but there's so much more to do in terms of gaining access for people around the globe that could benefit from our technology,' Leach said. Leach also listed continued innovation as a priority, with a focus on features that benefit the Dexcom's users as the company reaches a broader group of people. At the end of Wednesday's call, Sayer reiterated that he will still be involved with Dexcom for the next five months and plans to set up the company's new leaders for success. 'I'm not riding the retirement wave out of here,' Sayer said. Editor's note: This article has been updated with additional details and comments from analysts. Recommended Reading Dexcom COO on 15-day glucose sensor, Type 2 coverage Sign in to access your portfolio
